EcoDrugPlus

60s Ribosomal Protein L39

Ensembl ID : ENSVVUG00000016595
Gene Symbol: LOC112916430
3 Cross references
31 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSVVUG00000004075
Gene Symbol: LOC112922044
3 Cross references
66 Possible Orthologues:

60s Ribosomal Protein L7-Like

Ensembl ID : ENSVVUG00000018173
Gene Symbol: LOC112907228
2 Cross references
183 Possible Orthologues:

60s Ribosomal Protein L7a

Ensembl ID : ENSVVUG00000027293
Gene Symbol: LOC112911883
2 Cross references
129 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSVVUG00000017534
Gene Symbol: ARAF
3 Cross references
190 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSVVUG00000027674
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSVVUG00000002136
Gene Symbol: ADAM17
3 Cross references
282 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSVVUG00000024252
Gene Symbol: ADAMTS5
3 Cross references
200 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSVVUG00000015782
Gene Symbol: ADRM1
1 Cross references
255 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSVVUG00000003207
Gene Symbol: AKT1
3 Cross references
213 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSVVUG00000005880
Gene Symbol: AKT2
3 Cross references
253 Possible Orthologues:

Akt Serine/threonine Kinase 3

Ensembl ID : ENSVVUG00000026493
Gene Symbol: AKT3
3 Cross references
201 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).